Cruz-Chacon Alexis, Mathews John, Ayala Ernesto
Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA.
Cancer Control. 2014 Oct;21(4):335-42. doi: 10.1177/107327481402100410.
Some uncommon lymphoproliferative and histiocytic disorders may present with an aggressive course and require hematopoietic stem cell transplantation (HSCT) as part of the therapeutic approach.
Published research on the use of HSCT for the treatment of these disorders was reviewed and summarized.
Allogeneic HSCT may be indicated in patients with blastic plasmacytoid dendritic cell neoplasia, familial or secondary recurrent hemophagocytic lymphohistiocytosis, and resistant Langerhans cell histiocytosis. Autologous HSCT may be considered in patients with Castleman disease resistant to treatment. No role has been established for the use of HSCT for dendritic cell sarcoma.
HSCT has an evolving role in the treatment of select aggressive lymphoproliferative and histiocytic disorders.
一些罕见的淋巴增殖性和组织细胞性疾病可能呈侵袭性病程，需要将造血干细胞移植（HSCT）作为治疗方法的一部分。
对已发表的关于使用HSCT治疗这些疾病的研究进行了综述和总结。
异基因HSCT可能适用于母细胞性浆细胞样树突状细胞肿瘤、家族性或继发性复发性噬血细胞性淋巴组织细胞增生症以及难治性朗格汉斯细胞组织细胞增生症患者。对于治疗抵抗的Castleman病患者可考虑自体HSCT。HSCT在树突状细胞肉瘤的治疗中尚无明确作用。
HSCT在某些侵袭性淋巴增殖性和组织细胞性疾病的治疗中作用不断演变。
